Upcoming landmark decisions and reviews of the FDA’s rare disease policies will test the agency’s stance on biomarker-based accelerated approvals for orphan drugs. Regulatory unpredictability highlighted in some analytical reports provides larger pharmaceutical companies competitive advantages over emerging biotechs, while certain therapeutic areas such as psychedelics may benefit from these shifts. The evolving regulatory landscape prompts ongoing scrutiny and adaptation within biotech firms developing treatments for rare and orphan diseases.